RTK has supported multiple life sciences companies in achieving their strategic
goals by leveraging our extensive industry knowledge in technology and healthcare.
Unravel Biosciences is a therapeutics company founded on the principle that biological networks inform clinical outcomes. By using primary patient data with AI systems biology computation, rapid in vivo screening, and clinical validation of discovered targets, Unravel enables drug development with unprecedented efficiency. Unravel leverages its proprietary BioNAV™️ platform combining target and drug prediction with patient stratification by efficacy and toxicity response to find treatments for complex diseases. Unravel’s platform has led to two clinical trials starting in 2025. Unravel’s platform developed RVL002, a first-in-class new small molecule targeting mitochondrial metabolism, and RVL027 and RVL068, molecules targeting two novel mechanisms to treat dystonias. The rareSHIFT™️ program provides platform access to foundation and biotech partners to accelerate and clinically derisk therapeutics.
ROMEG Therapeutics, LLC, is a privately held, revenue-generating, specialty pharmaceutical company based in Woburn, Mass. The company’s mission is to develop new FDA-approved therapies by formulating novel dosage forms, improving the design and function of existing approved drugs, and expanding clinical indications for use of those drugs, thereby bringing greater value to earlier scientific discovery. The company’s first FDA-approved drug, Gloperba®️ (colchicine oral solution) was launched by commercial partner Scilex in the US in 2024. The company has two active pipeline programs targeting Sjogren’s syndrome, and continues to focus on developing a broad intellectual property portfolio to offer novel therapies to provide patients and physicians better treatment options.
RxM Therapeutics, a new drug venture created by CutisPharma, is focused on developing and commercializing FDA-approved drugs to meet the needs of patients, such as children and the elderly, who are unable to take tablets and capsules and need a high quality, palatable alternative formulation of their therapy to address their needs. Successful, FDA-approved drugs initially developed by the RxM venture with CutisPharma include FIRVANQ®️ (vancomycin hydrochloride for oral solution), Konvomep®️ (omeprazole and sodium bicarbonate for oral suspension) and FLEQSUVY®️ (baclofen oral suspension)
Exited investment in 2018, acquired by Novaquest Capital Management
CutisPharma’s FIRST®️ Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by commercially available therapies. The Company’s first FDA-approved Kit, FIRVANQ®️ (vancomycin hydrochloride for oral solution), allowed significantly broader patient access, convenience to pharmacists and patients alike by reducing the need for compounding, and serve as a potential cost-saving option to existing treatments.
Exited investment in 2018, acquired by Novaquest Capital Management
RTK is a biopharmaceutical advisory and investment fund that supports companies
by enabling them to develop promising technologies and reach their potential to benefit patients.
We have one goal: to enable better patient lives and a better world through better healthcare. We take great satisfaction in partnering with companies having high potential to disrupt the healthcare ecosystem and helping support high‐performing management teams to realize their goals.